Navidea's Lymphoseek meets clinical trial goals for new indication

10/11/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals announced that a Phase III trial of Lymphoseek, its technetium Tc-99m tilmanocept imaging agent, met study goals in terms of sensitivity, negative predictive value and overall accuracy of nonsentinel lymph node diagnosis in assessment of cancer in the head or mouth. The company may submit a supplemental new drug application by the end of the year based on the positive study results.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC